Cochrane Review Group

Schizophrenia

168 systematic reviews in Schizophrenia ask 2,589 questions. 23.2% have no studies to answer them, 27.8% rest on very low certainty evidence and 12.2% reach moderate or high certainty.

Reviews

168

Questions

2,589

current versions

No studies

23.2%

Moderate or high

12.2%

No studies 601 · 23.2%Ungraded 446 · 17.2%Very low 721 · 27.8%Low 505 · 19.5%Moderate 274 · 10.6%High 42 · 1.6%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Schizophrenia

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Summary of findings table ‐ Collaborative care vs usual care Quality of life: average change in mental health component (proxy for binary quality of life) · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane	no estimate extracted	3 studies · 227 participants	Very low
Summary of findings table ‐ Collaborative care vs usual care Quality of life: average change in physical health component (proxy for physical health) · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane	no estimate extracted	3 studies · 237 participants	Very low
Summary of findings table ‐ Collaborative care vs usual care Personal recovery ‐ not reported · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane	no estimate extracted	NR	No studies
Summary of findings table ‐ Collaborative care vs usual care Experience of care/satisfaction ‐ not reported · severe mental illness Collaborative care approaches for people with severe mental illness (2024) · Cochrane	no estimate extracted	NR	No studies
Structured risk assessment vs standard professional care Adverse effects (escape) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane	RR 0.2 [0.01, 4.11]	1 study · 200 participants	Very low
Structured risk assessment vs standard professional care Adverse effects (fall down) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane	RR 0.33 [0.04, 3.15]	1 study · 200 participants	Very low
Structured risk assessment vs standard professional care Adverse effects (choking) · aggressive behaviour in schizophrenia Risk assessment for aggressive behaviour in schizophrenia (2024) · Cochrane	RR 0.2 [0.01, 4.11]	1 study · 200 participants	Very low
Summary of findings table ‐ Cognitive behavioural therapy plus standard care vs control Adverse events ‐ participants with at least one adverse event ‐ < 12 months · first‐episode or recent‐onset psychosis Cognitive behavioural therapy added to standard care for first‐episode and recent‐onset psychosis (2024) · Cochrane	RR 1.29 [0.85, 1.97]	1 study · 43 participants	Very low
Summary of findings table ‐ CBT without antipsychotics vs antipsychotics Adverse events ‐ Participants with at least one AE (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane	RR 0.47 [0.21, 1.07]	1 study · 40 participants	Very low
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Mental state ‐ general: mean endpoint overall symptoms scales (PANSS/BPRS) (high = poor) (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane	no estimate extracted	3 studies · 125 participants	Very low
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Global state ‐ number of participants with relapse/exacerbations of psychosis (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane	RR 2.89 [0.12, 67.75]	1 study · 90 participants	Very low
Summary of findings table ‐ CBT without antipsychotics vs CBT plus antipsychotics Leaving the study early ‐ for any reason ‐ overall acceptability (separated time points) ‐ < 12 months · schizophrenia Cognitive behavioural therapy without medication for schizophrenia (2024) · Cochrane	RR 0.7 [0.12, 4.11]	2 studies · 90 participants	Very low

Reviews 168

Collaborative care approaches for people with severe mental illness

Reilly, S, Hobson-Merrett, C, et al. · Cochrane Database of Systematic Reviews · 2024

Schizophrenia

Thinnest evidence

Reviews 168

Collaborative care approaches for people with severe mental illness

Risk assessment for aggressive behaviour in schizophrenia

Cognitive behavioural therapy added to standard care for first‐episode and recent‐onset psychosis

Cognitive behavioural therapy without medication for schizophrenia

Magnetic seizure therapy for people with schizophrenia

Cognitive behavioural therapy plus standard care versus standard care for persistent aggressive behaviour or agitation in people with schizophrenia

Cognitive behavioural therapy (group) for schizophrenia

Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms

Pharmacological interventions for prevention of weight gain in people with schizophrenia

Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia

Antipsychotic dose reduction compared to dose continuation for people with schizophrenia

Video games for people with schizophrenia

Humour‐based interventions for people with schizophrenia

Parenting interventions for people with schizophrenia or related serious mental illness

Maintenance treatment with antipsychotic drugs for schizophrenia

Psychological interventions for psychosis in adolescents

Avatar Therapy for people with schizophrenia or related disorders

Specialised early intervention teams (extended time) for recent‐onset psychosis

Specialised early intervention teams for recent‐onset psychosis

Psychosocial interventions for people with both severe mental illness and substance misuse

Benzodiazepines for catatonia in people with schizophrenia or other serious mental illnesses

Modafinil for people with schizophrenia or related disorders

Peer support for people with schizophrenia or other serious mental illness

Treatments for primary delusional infestation

Haloperidol discontinuation for people with schizophrenia